Opioid misuse in the 30 days prior to entering agonist opioid treatment in four european countries. A pilot study

Heroin Addiction and Related Clinical Problems

Volumn 18, Issue 3, 2016, Pages 43-52

  Maremmani, Icro ^a,b,c   Somaini, Lorenzo ^d   Deruvo, Gaetano ^e   Maremmani, Angelo G I ^b,f   Touzeau, Didier ^g   Walcher, Tephan ^h   Fonseca, Francina ⁱ   Bacciardi, Silvia ^a,b   Guareschi, Marilena ^b   Green, Jody L ^j   McBride, Karin ^j   Dart, Richard C ^j,k  

^a UNIVERSITY OF PISA   (Italy)

^b Association for the Application of Neuroscientific Knowledge to Social Aims AU CNS   (Italy)

^c G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^d Addiction Treatment Centre   (Italy)

^e Addiction Unit (SERT) Bitonto   (Italy)

^f Region of Tuscany   (Italy)

^g Clinique Liberté   (France)

^h Hospital del Mar and IMIM ^*  (Germany)

ⁱ HOSPITAL DEL MAR   (Spain)

^j ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^k UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Agonist Opioid Treatment (AOT) medications; Opioid analgesic (OA) medications; Prescription Opioids (POs); Primary substance of abuse (PSA)

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CODEINE; DIAMORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; METHYLPHENIDATE; MORPHINE; OPIATE; OXYCODONE; OXYMORPHONE; TRAMADOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG MISUSE; EUROPE; FEMALE; FRANCE; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PILOT STUDY; PRESCRIPTION; PREVALENCE; PRIMARY SUBSTANCE OF ABUSE; PRIORITY JOURNAL; SPAIN; SUBSTANCE ABUSE;

EID: 84965111078     PISSN: 15921638     EISSN: 25314122     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Alho H., Littlewood R., Maremmani I. (2014): Defining a new approach to measuring outcomes in opioid dependence management:. Heroin Addict Relat Clin Probl. 16(2): 11-16.
2. Ballantyne J. C., Laforge K. S. (2007): Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 129(3): 235-255.
3. Banta-Green C. J., Merrill J. O., Doyle S. R., Boudreau D. M., Calsyn D. A. (2009): Opioid use behaviors, mental health and pain--development of a typology of chronic pain patients. Drug Alcohol Depend. 104(1-2): 34-42.
4. Cicero T. J., Ellis M. S., Surratt H. L., Kurtz S. P. (2014): The Changing Face of Heroin Use in the United States: A Retrospective Analysis of the Past 50 Years. JAMA Psychiatry. 71(7): 821-826.
5. Cleland C. M., Rosenblum A., Fong C., Maxwell C. (2011): Age differences in heroin and prescription opioid abuse among enrolees into opioid treatment programs. Subst Abuse Treat Prev Policy. 6: 11.
6. Compton W. M., Jones C. M., Baldwin G. T. (2016): Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. N Engl J Med. 374(2): 154-163.
7. Compton W. M., Volkow N. D. (2006): Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend.83 Suppl 1: S4-7.
8. Department of Health Administration (2007): Drug Misuse and Dependence: UK Guidelines on Clinical Management. Available at: Available at: wwwmerckmanualscom. Accessed on March 30, 2011.
9. Dertadian G. C., Maher L. (2014): From oxycodone to heroin: two cases of transitioning opioid use in young Australians. Drug Alcohol Rev. 33(1): 102-104.
10. Dole V. P. (1971): Methadone maintenance treatment for 25,000 heroin addicts. JAMA. 215(7): 1131-1134.
11. Dole V. P. (1972): Comments on “heroin maintenance”. JAMA. 220(11): 1493.
12. Dole V. P. (1972): Narcotic addiction, physical dependence and relapse. N Engl J Med. 286(18): 988-992.
13. Dole V. P. (1999): Methadone Maintenance. Comes of age. Heroin Addict Relat Clin Probl. 1(1): 13-17.
14. Emccdda (2011): Annual report 2011: the state of the drugs problem in Europe. Amphetamines, ecstasy, hallucinogens, GHB and ketamine. Available at: http://www.emcdda.europa.eu/online/annual-report/2011/ amphetamines/3 [accessed January 16, 2012]
15. Forrester M. B. (2012): Temporal and geographic patterns in opioid abuse in Texas. J Addict Dis. 31(2): 93-99.
16. Gilson A. M., Kreis P. G. (2009): The burden of the nonmedical use of prescription opioid analgesics. Pain Medicine. 10(supp 2): S89-S100.
17. Grau L. E., Dasgupta N., Harvey A. P., Irwin K., Givens A., Kinzly M. L., Heimer R. (2007): Illicit use of opioids: is OxyContin a “gateway drug”? Am J Addict. 16(3): 166-173.
18. Inciardi J. A., Surratt H. L., Cicero T. J., Beard R. A. (2009): Prescription opioid abuse and diversion in an Urban community: The results of an ultrarapid assessment. Pain Medicine. 10(3): 537-548.
19. Khosla N., Juon H. S., Kirk G. D., Astemborski J., Mehta S. H. (2011): Correlates of non-medical prescription drug use among a cohort of injection drug users in Baltimore City. Addict Behav. 36(12): 1282-1287.
20. Kuehn B. M. (2007): Prescription drug abuse rises globally. JAMA. 297(12): 1306.
21. Lankenau S. E., Teti M., Silva K., Bloom J. J., Harocopos A., Treese M. (2012): Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 23(1): 37-44.
22. Ling W., Mooney L., Hillhouse M. (2011): Prescription opioid abuse, pain and addiction: Clinical issues and implications. Drug Alcohol Rev. 30(3): 300-305.
23. Maremmani I. (2015): Controversy or misunderstanding? Heroin Addict Relat Clin Probl. 17(2-3): 5-8.
24. Maremmani I., Gerra G., Ripamonti C. I., Mugelli A., Allegri M., Vigano R., Romualdi P., Pinto C., Raffaeli W., Coluzzi F., Gatti R. C., Mammucari M., Fanelli G. (2015): The prevention of analgesic opioids abuse: an expert opinion. Eur Rev Med Pharmacol Sci. 19: 4203-4206.
25. Maremmani I., Guareschi M., Deruvo G., Somaini L., Maremmani A. G. I., Green J., Mcbride K., Dart R. C. (2015): Prescription opioids (substitution medications and pain medications) in patients looking for Opioid Agonist Treatment in Northern and Southern Italy, using a 18-month survey methodology. Heroin Addict Relat Clin Probl. 17(1): 33-42.
26. Maremmani I., Maremmani A. G. I. (2015): Towards the future of the treatment of heroin addiction. New challenges/issues to be addressed. Heroin Addict Relat Clin Probl. 17(4): 5-8.
27. Maremmani I., Shinderman M. S. (1999): Alcohol, benzodiazepines and other drugs use in heroin addicts treated with methadone. Polyabuse or undermedication? Heroin Addict Relat Clin Probl. 1(2): 7-13.
28. Martel M. O., Wasan A. D., Jamison R. N., Edwards R. R. (2013): Catastrophic thinking and increased risk for prescription opioid misuse in patients with chronic pain. Drug Alcohol Depend. 132(1-2): 335-341.
29. Morasco B. J., Turk D. C., Donovan D. M., Dobscha S. K. (2013): Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend. 127(1-3): 193-199.
30. Parrino M., Maremmani A. G. I., Samuels P. N., Maremmani I. (2015): Challenges and Opportunities for the use of medications to treat Opioid Addiction in the United States and Other Nations of the world. J Addict Dis. DOI:10.1080/10550887.2015.1059113
31. Reisinger M. (2014): How to treat the treatment system. Heroin Addict Relat Clin Probl. 16(1): 45-48.
32. Rosenblum A., Parrino M., Schnoll S. H., Fong C., Maxwell C., Cleland C. M., Magura S., Haddox J. D. (2007): Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 90(1): 64-71.
33. Roy E., Arruda N., Bourgois P. (2011): The growing popularity of prescription opioid injection in downtown Montreal: new challenges for harm reduction. Subst Use Misuse. 46(9): 1142-1150.
34. Siegal H. A., Carlson R. G., Kenne D. R., Swora M. G. (2003): Probable relationship between opioid abuse and heroin use. Am Fam Physician. 67(5): 942, 945.
35. Sites B. D., Beach M. L., Davis M. A. (2014): Increases in the use of prescription opioid analgesics and the lack of improvement in disability metrics among users. Reg Anesth Pain Med. 39(1): 6-12.
36. Sun M. (1982): Heroin, morphine found comparable as pain-killer. Science. 216(4543): 277.
37. Ulmer A., Lamy D., Reisinger M., Haraldsen M., Maremmani I., Newman R. (2012): How should Methadone-and Buprenorphine-Treatment be organized and regulated? A comparison of two systems in the context of an Europad-conference in Brussels. Heroin Addict Relat Clin Probl. 14(1): 5-10.
38. Verheul R., Van Den Brink W., Geerlings P. (1999): A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 34(2): 197-222.
39. Zosel A., Bartelson B. B., Bailey E., Lowenstein S., Dart R. (2013): Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS((R))) System. J Am Acad Child Adolesc Psychiatry. 52(2): 196-204 e192.